ImmunityBio
IBRX
9.75
+0.06
+0.62%
ImmunityBio
US · IBRX
#1397 by market cap
Listed 1970
9.75
+0.06
+0.62%
Live - 5344 symbols - heartbeat 353s ago
· 2026-10-08 07:37
Pre-market
9.65
-1.03%
After-hours
9.77
+0.16%
Overnight
9.70
-0.51%
- Market cap
- 10.33B
- P/E (TTM)i
- -10.26
- P/Bi
- -9.87
- EPSi
- -0.38
- Div yieldi
- 0.00%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on IBRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -5.06, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year +668.31% YoY
Margins
- Gross margin
- 99.34%
- Operating margin
- -226.00%
- Net margin
- -310.18%
Key ratios & quality
- Enterprise valuei
- 10.58B
- Altman Z-Scorei
- -5.06
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.20M | 605.00K | 934.00K | 240.00K | 622.00K | 14.75M | 113.29M |
| Gross profit | -- | -- | -- | 240.00K | 622.00K | 14.75M | 112.54M |
| Selling & admin expenses | 46.46M | 71.32M | 135.26M | 102.71M | 129.62M | 168.78M | 150.00M |
| Research & development | 112.00M | 139.51M | 195.96M | 248.15M | 232.37M | 190.14M | 218.56M |
| Operating profit | -156.25M | -210.22M | -330.28M | -350.62M | -361.36M | -344.18M | -256.03M |
| Pretax profit | -160.26M | -226.03M | -349.84M | -417.29M | -583.89M | -413.65M | -351.61M |
| Tax | -105.00K | -1.85M | 9.00K | 34.00K | -40.00K | 0 | -135.00K |
| Net profit | -160.16M | -224.19M | -349.85M | -417.32M | -583.85M | -413.65M | -351.47M |
| Basic EPS | 0 | -1 | -1 | -1 | -1 | -1 | 0 |
| Diluted EPS | -0.41 | -0.58 | -0.89 | -1.04 | -1.15 | -0.62 | -0.38 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 16.52M | 26.43M | 32.06M | 38.29M | 44.21M | 51.24M |
| Gross profit | 16.46M | 26.29M | 31.88M | 37.90M | 43.97M | 50.94M |
| Selling & admin expenses | 32.65M | 42.34M | 36.28M | 38.73M | 45.77M | 51.82M |
| Research & development | 48.23M | 55.24M | 51.23M | 63.86M | 67.99M | 60.82M |
| Operating profit | -64.43M | -71.29M | -55.63M | -64.68M | -69.79M | -61.70M |
| Pretax profit | -129.90M | -92.31M | -67.31M | -62.09M | -632.79M | -230.39M |
| Tax | -234.00K | 269.00K | -35.00K | -135.00K | 9.00K | 0 |
| Net profit | -129.67M | -92.57M | -67.27M | -61.96M | -632.80M | -230.39M |
| Basic EPS | 0 | 0 | 0 | 0 | -1 | 0 |
| Diluted EPS | -0.15 | -0.10 | -0.07 | -0.06 | -0.62 | -0.22 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | -- | 111.71M | 334.35M | 140.58M | 294.08M | 184.59M | 314.88M |
| Cash & ST investments | -- | 96.06M | 317.12M | 107.18M | 266.46M | 149.81M | 242.82M |
| Inventory | -- | -- | -- | -- | 0 | 8.27M | 910.00K |
| Total assets | -- | 221.38M | 468.91M | 362.36M | 504.45M | 382.93M | 501.90M |
| Total current liabilities | -- | 68.13M | 369.00M | 500.86M | 58.28M | 54.94M | 61.75M |
| Short-term debt | -- | 5.02M | 302.25M | 434.55M | 5.24M | 7.47M | 7.54M |
| Long-term debt | -- | 254.35M | 306.35M | 241.27M | 681.54M | 461.88M | 477.09M |
| Total liabilities | -- | 339,871,000.00 | 712,823,000.00 | 812,176,000.00 | 1,090,389,000.00 | 871,062,000.00 | 1,001,472,000.00 |
| Total equity | -- | -118.49M | -243.91M | -449.82M | -585.94M | -488.13M | -499.57M |
| Retained earnings | -- | -1.62B | -1.96B | -2.38B | -2.96B | -3.38B | -3.73B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 109.16M | 208.13M | 329.50M | 314.88M | 452.95M | 438.98M |
| Cash & ST investments | 61.59M | 153.66M | 257.81M | 242.82M | 380.88M | 357.37M |
| Inventory | 8.44M | 6.64M | 6.70M | 910.00K | 547.00K | 1.94M |
| Total assets | 303.76M | 402.08M | 518.99M | 501.90M | 646.64M | 628.50M |
| Total current liabilities | 49.21M | 50.64M | 57.13M | 61.75M | 67.95M | 76.73M |
| Short-term debt | 7.46M | 7.39M | 7.32M | 7.54M | 7.63M | 7.51M |
| Long-term debt | 485.72M | 492.08M | 500.80M | 477.09M | 678.39M | 774.35M |
| Total liabilities | 894,241,000.00 | 971,895,000.00 | 1,042,397,000.00 | 1,001,472,000.00 | 1,515,763,000.00 | 1,674,265,000.00 |
| Total equity | -590.48M | -569.82M | -523.41M | -499.57M | -869.13M | -1.05B |
| Retained earnings | -3.50B | -3.60B | -3.66B | -3.73B | -4.36B | -4.59B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -152.11M | -171.72M | -274.42M | -337.51M | -366.76M | -391.24M | -304.94M |
| Depreciation & amortization | 14.04M | 12.74M | 14.24M | 18.26M | 18.51M | 17.55M | 15.53M |
| Free cash flow | -156.40M | -173.39M | -307.98M | -436.90M | -397.34M | -398.12M | -309.19M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 27.50M | 86.30M | 164.53M | 60.43M | 100.56M | 111.36M | 400.56M |
| Ending cash balance | 75.98M | 35.09M | 181.28M | 104.97M | 265.79M | 143.91M | 89.43M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -85.91M | -79.75M | -68.91M | -70.38M | -75.36M | -66.49M |
| Depreciation & amortization | 3.83M | 3.88M | 3.95M | 3.87M | 4.38M | 4.41M |
| Free cash flow | -87.03M | -80.83M | -69.68M | -71.65M | -77.15M | -70.03M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 173.14M | 173.68M | 53.74M | 102.23M | 45.05M |
| Ending cash balance | 61.14M | 138.14M | 61.34M | 89.43M | 206.47M | 76.95M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- | -- |
| ROA %i | -- | -100.21 | -100.48 | -100.22 | -134.56 | -93.21 | -79.43 |
| ROIC %i | -- | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -7,009.22 | -35,860.99 | -35,866.17 | -147,404.58 | -73,101.93 | -1,912.42 | -211.04 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | 1.64 | 0.91 | 0.28 | 5.05 | 3.36 | 5.10 |
| Quick ratioi | -- | 1.44 | 0.86 | 0.22 | 4.63 | 2.77 | 4.62 |
| Debt / assetsi | -- | 124.47 | 137.69 | 199.74 | 144.06 | 131.66 | 103.22 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -26.07 | -23.91 | -22.56 | -5.57 | -3.52 | -2.14 | -2.12 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -52.23 | 0.93 | 150.86 | 678.62 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | -116.15 | -86.74 | -78.91 | -79.43 | -179.83 | -192.58 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -899.46 | -449.18 | -300.96 | -211.04 | -526.59 | -529.64 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.22 | 4.11 | 5.77 | 5.10 | 6.67 | 5.72 |
| Quick ratioi | 1.61 | 3.48 | 5.10 | 4.62 | 6.24 | 5.35 |
| Debt / assetsi | 173.25 | 133.14 | 104.48 | 103.22 | 111.22 | 129.36 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -2.18 | -2.25 | -2.48 | -2.12 | -6.62 | -7.67 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Product revenue, net is the largest reported line at 98.89% of revenue, across 2 reported segments.
- The next-largest line, Other revenues, is a distant second at 1.11% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Product revenue, net98.89%
Other revenues1.11%
Quote time 2026-10-08 07:37:04 · For reference only, not investment advice and not tailored to your situation.